Eligo Bioscience, a biotech company based in France, has raised a $20 million Series A round from Khosla Ventures and Seventure Partners together with a $2 million award from Worldwide Innovation Challenge.
Eligo is developing a biotherapeutic platform – dubbed the eligobiotics platform – that uses nanobots to engineer microbiomes in the development of precision medicine to treat bacteria-related diseases and to stem antibiotic resistance.
The new funds will be invested in further development of the platform as well as growing its team of engineers and scientists to begin clinical trials.
“Antibiotics are weapons of mass destruction: extremely powerful but imprecise,” said Dr Xavier Duportet, CEO of Eligo. “With eligobiotics, we can precisely intervene on the microbiome – targeting specific bacteria for interventions of our choice. By engineering the microbiome itself with sniper-like precision, we can address the cause, not just the symptoms, of bacteria-associated diseases.”
Eligo was founded in Paris in 2014 by professors and alumni of MIT and Rockefeller University.